おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Alladapt Immunotherapeutics
company
About
Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy.
- 11 - 50
Highlights
Details
- Last Funding Type
- Debt Financing
- Last Funding Money Raised
- $50M
- Industries
- Biotechnology
- Founded date
- Jan 1, 2018
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$50M
Alladapt Immunotherapeutics has raised a total of
$50M
in funding over 2 rounds. Their latest funding was raised on
Aug 30, 2022 from a Debt Financing round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 30, 2022 | Debt Financing | $50M | 1 |
Hercules Capital
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Alladapt Immunotherapeutics is funded by 1 investors.
Hercules Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Debt Financing |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
